Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O’Connell, Chief Executive Officer. Dr. Doherty’s responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions.
Related news for (ABOS)
- Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
- Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
- Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
- Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
- Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers